Post COVID-19 Pandemic: New Frontiers and Opportunities of Antibody-based Biologics

Biocytogen

Premium

Biocytogen provides integrated solutions for next-generation antibody drug discovery to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for antibody drug discovery and validation, including humanized animal model generation, therapeutic antibody discovery, and preclinical pharmacology studies.

BGI

Premium

BGI Americas, the US subsidiary of BGI Genomics, is the leading provider of genomics and proteomics services. We operate in three business areas: next-generation sequencing, mass spectrometry, and IVD. Serving customers in genetics research, pharmaceutical R&D, and disease diagnostics, we are committed to advancing technologies and applications to benefit the mankind.
BGI Americas是华大基因旗下美国子公司，是领先的基因组学和蛋白质组学服务供应商。我们致力于高通量测序、质谱分析和体外诊断三个业务领域，服务于基因组学研究、医药研发和疾病诊断领域的客户。我们始终坚持推动科技成果的转化和应用，实现基因科技造福人类的目标。

Bon Opus

Premium

Bon Opus Biosciences is a fast-growing biotech company providing essential reagents to life science community. Our team has decades of experience in designing and manufacturing high-quality recombinant proteins as well as recombinant antibodies. Our clientele includes thousands of researchers across both academia and industry sectors all over the world. The scope of CRO services offered ranges from gene synthesis, peptide synthesis to recombinant protein expression, and recombinant antibody production. We also carry a catalog of over 4,000 recombinant protein products – from cytokines, growth factors, immune checkpoints, to neurodegeneration products. Highlights: Gene synthesis with 100% accuracy, cloning into your vector >90% success rate over thousands of recombinant protein projects expressed in 4 systems: E.coli, mammalian, yeast, and baculovirus High QC standard: Low endotoxin <0.1EU/mg, SEC purity >98% Variable modalities: mAb, ScFv, Fab, VHH, and Bi-Specific Ab Guaranteed delivery time: built upon operational and logistic excellence, we deliver on time as promised Website: https://www.bonopusbio.com/

DetaiBio

Premium

Detai Bioengineering Co., Ltd. (“DetaiBio”), established in 2013, is a CRO vendor focusing on antibody discovery and functional protein research field. DetaiBio is aiming to provide high quality and economic offer service to speed up life science for our client in different fields, such as antibody drug discovery, in-vitro diagnosis and academic research. Currently, DetaiBio has established different platforms including FACS sorting, plasma cell sorting, hybridoma sequencing, single cell sequencing, structure analysis, high-throughput recombinant protein/antibody, stable cell line development etc, to support service upgrading, internal R&D and high QC standard. The main services offer by DetaiBio: ----SingleB® for antibody/VHH discovery service ---- High-throughput recombinant antibody expression service (2 weeks delivery), ----Hybridoma sequencing service ----Customize protein expression service ( E.coli, Mammalian) Detaibio will continue more efforts to accelerate the research in life science (biotech and biopharma industry, IVD and academic field), to achieve the win-win for both DetaiBio and our partners.

GemPharmatech

Premium

GemPharmatech is a leading contract research organization that provides genetically engineered mouse models (GEMMs) and services to global preclinical R&D communities. We provide an expansive array of preclinical services, including mouse model customization, pharmacology services such as drug efficacy testing and mouse phenotyping, CRISPR/Cas9 gene-editing, cryopreservation, rapid expansion, and customized breeding.

HJB

Premium

HJB has full CMC development capabilities for all protein therapeutics. HJB employs leading technology platforms to substantially accelerate R&D and reduce costs. We offer flexible, reliable, and quality development and manufacturing services for the entire lifecycle of drug development from research to DS/DP manufacturing, and regulatory support.

HuaBio

Premium

Hangzhou HuaAn biotechnology Co.Ltd (referred to as "Huabio") was established in 2007 and headquartered in Hangzhou, Zhejiang. Huabio is committed to providing the highest quality antibodies. Huabio's catalogue products include recombinant rabbit monoclonal antibodies, mouse monoclonal antibodies, alpaca antibodies, ADC drug small molecule detection antibodies, ELISA and matched antibody pairs, and recombinant proteins. Huabio offers a wide range of custom antibody services including antibody development, bulk antibody production, antibody conjugation, and hybridoma production. Huabio's HiMab™ technology is able to generate a large number of high-quality rabbit mAbs within three months. Our rabbit mAb discovery technology involves sorting, cloning of rabbit B cells, and high throughput (HTP) antibody production. HiMab™ platform generate high-specificity, high-affinity mAbs towards a wide range of difficult targets such as small molecules, Ab drugs, and protein post-translational modifications (PTMs) .

Innostar

Premium

Shanghai InnoStar Biotech Co., Ltd. (InnoStar), a subsidiary of the China National Pharmaceutical Industrial Research Institute Co., Ltd., China National Pharmaceutical Group, was established in 2010. As a leading contract research organization, we adhere to the core values of “Science orientated, Quality first, Integrity &amp; dedication, Win-win cooperation”, strive for excellence through our services with high quality, win customers by recognized reputation, add values by technical innovation, and maintain efficiency by streamlined management. Over the past decade, InnoStar has successfully passed GLP inspections by various national and international regulatory authorities, including US FDA, and received GLP certification from the National Medical Products Administration (NMPA), OECD GLP certification from the Netherlands GLP monitoring authority, AAALAC certification, and CAP certification from the College of American Pathologists (CAP), etc. Our business scope covers early-stage druggability assessment, nonclinical pharmacodynamics, nonclinical pharmacokinetics, nonclinical safety evaluation, clinical sample bioanalysis, and biomarkers and translational research.

Joinn

Premium

Protheragen

Premium

Protheragen’s business has been growing rapidly since founded in Ronkonkoma, New York, USA. We serve as a global business development partner for biotech/pharmaceutical companies and have built close relationships with many investment companies. To further our development, part of our strategies require us to constantly seek high-quality novel drug research and development programs that are open to collaboration opportunities. Collaborative Development Protheragen aims to collaborate with biopharmaceutical companies around the world to develop new drugs, particularly the development of treatments for rare diseases. We specialize in developing precise animal models to accelerate the development of orphan drugs. Project Incubation Protheragen designs and implements the most suitable development strategy to help external entrepreneurs and pharmaceutical companies incubate innovative drug development programs. Project Transfer Relying on strong industry resources and connections built up throughout the years, Protheragen searches and connects the perfect licensees and partners for our clients. Contact Us E-mail: info@protheragen.com (Resumes accepted at this email address)

XtalPi

Premium

Founded in 2014, XtalPi founders recognized a common hurdle in drug development having to do with solid polymorphism, which they successfully tackled with quantum physics predictions. Since then, XtalPi has maintained its focus on identifying and then attacking traditional bottlenecks in biopharmaceutical R&D through innovative technologies. Through considerable capital investments in automation and personnel, XtalPi now has four locations worldwide and employs approximately 1000 employees. XtalPi has engaged in collaboration research with nearly all top-20 pharmaceutical companies in the world. Its ID4 platform combines physics-based simulations with experimental validation and refinement, automation for rapid syntheses, and machine learning to continuously improve prediction accuracy and process efficiency. Similarly XupremAb, XtalPi's next-generation platform for therapeutic antibody discovery, combining traditional wet-lab techniques with state-of-the-art AI & automation technologies to generate better antibody candidates faster.

WuXi Biologics

Premium

WuXi Biologics is a global CRDMO with leading open-access biologics technology platforms.  Our end-to-end solutions enable our partners to discover, develop, and manufacture biologics and vaccines from concept to commercialization for patients worldwide. With total estimated capacity for biopharmaceutical production planned in five countries at 580,000L after 2026, we will provide our partners with a premier-quality Global Dual Source supply chain network.